FDA Approves Leucovorin for Rare Genetic Condition
The FDA will extend approval for leucovorin, a drug only for cerebral folate deficiency (CFD), not for autism. CFD, a genetic condition, shares some symptoms with autism. This decision highlights the FDA's focus on specific genetic disorders, reported the Washington Post.
The U.S. Food and Drug Administration is set to announce extended approval for the drug leucovorin, but its use will be limited to treating a rare genetic condition, not autism itself, according to the Washington Post.
The condition, cerebral folate deficiency (CFD), can manifest with symptoms that resemble autism, prompting the FDA's cautious endorsement.
This move underscores the FDA's precision in approving treatments for specific genetic disorders, rather than broader developmental conditions.
ALSO READ
-
FDA Expands Leucovorin Approval for Rare Genetic Disorder
-
FDA Approval and Drug Market Collaborations: A Health Sector Update
-
FDA Vaccine Chief Leaves Amid Controversy, Again
-
Current Health Headlines: New Moves in Medical Education, Drug Production, and FDA Warnings
-
FDA Challenges UniQure's Huntington's Disease Gene Therapy Trial
Google News